Short answer
BridgeBio Pharma, Inc. (BBIO) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $244M (up 120.4% year over year) with net income of −$152M.
Q2 2026 key financials · XBRL
- Revenue
- $244M
- +120.4% YoY · +25.3% QoQ
- Net income
- −$152M
- +16.3% YoY · +7.2% QoQ
- Operating margin
- -43.9%
- EPS (diluted)
- −$0.78
- +18.7% YoY · +7.1% QoQ
Source: XBRL data from the BridgeBio Pharma, Inc. (BBIO) Q2 2026 10-Q on SEC EDGAR. USD.
BridgeBio Pharma, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $243.7M, up $133.1M YoY from $110.6M, driven by Attruby product revenue $222.4M
- Best-performing line Attruby, product revenue up $150.9M YoY; royalty revenue increased $13.8M to $15.4M
- Operating loss $107.1M vs $134.3M YoY; operating margin 43.9% loss vs 121.4% loss
- Cash, equivalents and securities $720.2M vs $587.5M at December 31, 2025
- Capital deployment included $127.5M share repurchases; $933.9M preferred-stock investment raised
- Outlook: continued operating and net losses expected for at least the next several years; commercialization and development remain key risks
Risk Factors
- Convertible Notes: 2027 and 2031 Notes became convertible July 1–September 30, 2026, potentially reducing liquidity through cash settlement
- Preferred Stock: July 2026 issuance of 933,900 shares convertible into 6,777,704 common shares, creating material dilution risk
- Royalty obligations: Attruby royalty rate may increase from 5% to 10% in 2027, pressuring liquidity and profitability
- Equity financing: May 2026 at-the-market program permits sales of up to $500.0 million, risking dilution and share-price pressure
- Covenant compliance: Royalty arrangements require collateral-backed obligations and operational restrictions, with violations exposing assets to remedies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BridgeBio Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.